CELLINK’s bioink and bioprinters are being used in several progressive research areas

This Press release summarizes some of the recent advancements and validations made with CELLINK’s technology.

Cellulose Hydrogel for 3D Printability 

Researchers at North Dakota State University test printability, shape fidelity and cell viability of sodium alginate with carboxymethyl cellulose (CMC) used in 3D bio-printing. The bioink being used in the study was CELLINK’s bioink. The result of the study showed that this hybrid hydrogel can be a biomaterial in 3D bioprinting and allows characterization techniques for printability and shape fidelity.

CELLINK Collaborators Research Neuromuscular Junction Development in Suspended Hydrogel Arrays

The CELLINK Inkredible+ is being used in the research of neuromuscular junction development in suspended hydrogel arrays. Researchers at Tufts University show the application of 3D bioprinting as a tool to recapitulate the physiology of the neuromuscular connection to enable researchers to better understand the development, maturation as well as degeneration of neuromuscular junctions. The platform described is fully customizable using 3D freeform printing through CELLINK’s Inkredible+ bioprinter into standard laboratory tissue culture materials. It also allows for human myoblast alignment in 3D with precise motoneuron integration into preformed myotubes. The coculture method will ideally be useful in observation and analysis of neurite outgrowth and myogenic differentiation in 3D with quantification of several parameters of muscle innervation and function.

CELLINK Collaborator Mimicks Bone Marrow Vascular Niche with Multi-Channel Silk Sponge 

Researchers at Tufts University, University of Pavia, and IRCC San Matteo Foundation created a custom perfusion chamber to contain a multi-channel lyophilized silk sponge that mimics the vascular network in the bone marrow niche. CELLINK’s Inkredible printer was used in this study to create the sponges. Cylinders of the silk sponges were Permeability analysis was performed based on a custom configured device. Cylinders of the glycerol doped silk sponges were inserted in CELLINK’s Inkredible cartridges.

CELLINK at Termis World Congress 2018
CELLINK is attending the Termis World Congress in Kyoto, Japan. CELLINK will during the conference present new results and advancements made and participate in poster sessions. To learn more about our products and technology, please visit us at booth No.14 in the Event Hall, or in booth No. 60 at the exhibition hall.

For further information, please contact:

Erik Gatenholm, CEO                                                                        Gusten Danielsson, CFO

Phone: +46 73 267 00 00                                                                 Phone: +46 70 991 86 04

E-mail: eg@cellink.com                                                                   E-mail: gd@cellink.com

About CELLINK

CELLINK is the first bioink company in the world and the leading 3Dbioprinter provider that focuses on the development and commercialization of bioprinting technologies that allow researchers to 3D print human organs and tissues for the development of pharmaceutical and cosmetic treatments. Founded 2016 and active in more than 45 countries, CELLINK is changing the future of medicine as we know it. To read more about CELLINK, please visit: www.cellink.com  

Senaste pressreleaserna
November 14, 2018RegulatoryKallelse till årsstämma i CELLINK AB